These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32244346)

  • 1. Recent Strategic Advances in CFTR Drug Discovery: An Overview.
    Rusnati M; D'Ursi P; Pedemonte N; Urbinati C; Ford RC; Cichero E; Uggeri M; Orro A; Fossa P
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
    Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
    Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator.
    Collawn JF; Fu L; Bebok Z
    Expert Rev Proteomics; 2010 Aug; 7(4):495-506. PubMed ID: 20653506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance.
    Rusnati M; Sala D; Orro A; Bugatti A; Trombetti G; Cichero E; Urbinati C; Di Somma M; Millo E; Galietta LJV; Milanesi L; Fossa P; D'Ursi P
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29316712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Approaches for Potential Therapy of Cystic Fibrosis.
    Sawczak V; Getsy P; Zaidi A; Sun F; Zaman K; Gaston B
    Curr Drug Targets; 2015; 16(9):923-36. PubMed ID: 25557257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
    Amaral MD
    Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR.
    Kym PR; Wang X; Pizzonero M; Van der Plas SE
    Prog Med Chem; 2018; 57(1):235-276. PubMed ID: 29680149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CFTR: cystic fibrosis and beyond.
    Mall MA; Hartl D
    Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation-specific therapies and drug repositioning in cystic fibrosis.
    Villella VR; Tosco A; Esposito S; Bona G; Raia V; Maiuri L
    Minerva Pediatr; 2019 Jun; 71(3):287-296. PubMed ID: 30761820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases.
    Tassini S; Sun L; Lanko K; Crespan E; Langron E; Falchi F; Kissova M; Armijos-Rivera JI; Delang L; Mirabelli C; Neyts J; Pieroni M; Cavalli A; Costantino G; Maga G; Vergani P; Leyssen P; Radi M
    J Med Chem; 2017 Feb; 60(4):1400-1416. PubMed ID: 28122178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy.
    Kim Chiaw P; Eckford PD; Bear CE
    Essays Biochem; 2011 Sep; 50(1):233-48. PubMed ID: 21967060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis.
    Amaral MD; Farinha CM
    Curr Pharm Des; 2013; 19(19):3497-508. PubMed ID: 23331027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combating cystic fibrosis: in search for CF transmembrane conductance regulator (CFTR) modulators.
    Noy E; Senderowitz H
    ChemMedChem; 2011 Feb; 6(2):243-51. PubMed ID: 21275046
    [No Abstract]   [Full Text] [Related]  

  • 17. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
    Verkman AS; Lukacs GL; Galietta LJ
    Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability.
    Meng X; Clews J; Kargas V; Wang X; Ford RC
    Cell Mol Life Sci; 2017 Jan; 74(1):23-38. PubMed ID: 27734094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.